GAMMAGARD Liquid ERC
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- GAMMAGARD Liquid ERC
- Generic name
- IMMUNE GLOBULIN INFUSION (HUMAN)
- Manufacturer
- Takeda Pharmaceuticals America, Inc.
- Product type
- PLASMA DERIVATIVE
- SPL set ID
- 1341fd31-0754-47f0-a4d6-7255056b6541
- SPL ID
- 2332ff1f-1311-4aaa-9d76-9a011b3f7956
- Version
- 2
- Effective date
- 2025-10-30
- Source export date
- 2026-11-13
- Source partition
- 12
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0012-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/df974ce21ba33b4471866e2af5412327fbd4bcd68d14b42d7cfb3aa15d163738/drug-label-0012-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 17:54:50
| Harmonized routes |
|---|
| INTRAVENOUS, SUBCUTANEOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 125105 | derived:openfda.application_number |
| application number | BLA125105 | openfda.application_number | |
| brand name | GAMMAGARD Liquid ERC | openfda.brand_name | |
| generic name | IMMUNE GLOBULIN INFUSION (HUMAN) | openfda.generic_name | |
| manufacturer name | Takeda Pharmaceuticals America, Inc. | openfda.manufacturer_name | |
| ndc | package | 0944-2705-05 | openfda.package_ndc |
| ndc | package | 0944-2705-50 | openfda.package_ndc |
| ndc | package | 0944-2705-10 | openfda.package_ndc |
| ndc | package | 0944-2705-01 | openfda.package_ndc |
| ndc | product | 0944-2705 | openfda.product_ndc |
| ndc11 | package | 00944270550 | derived:openfda.package_ndc |
| ndc11 | package | 00944270501 | derived:openfda.package_ndc |
| ndc11 | package | 00944270505 | derived:openfda.package_ndc |
| ndc11 | package | 00944270510 | derived:openfda.package_ndc |
| rxcui | 2733847 | openfda.rxcui | |
| rxcui | 1809421 | openfda.rxcui | |
| rxcui | 1809414 | openfda.rxcui | |
| rxcui | 2733845 | openfda.rxcui | |
| spl id | 2332ff1f-1311-4aaa-9d76-9a011b3f7956 | id | |
| spl set id | 1341fd31-0754-47f0-a4d6-7255056b6541 | set_id | |
| unii | 66Y330CJHS | openfda.unii |
Boxed warning cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNING: THROMBOSIS, RENAL DYSFUNCTION and ACUTE RENAL FAILURE Thrombosis may occur with immune globulin products, including GAMMAGARD LIQUID ERC. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors [see Warnings and Precautions (5.4) ]. Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients with immune globulin intravenous (IGIV) products. Patients predisposed to renal dysfunction include those with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. GAMMAGARD LIQUID ERC does not contain sucrose [see Warnings and Precautions (5.2) ]. For patients at risk of thrombosis, administer GAMMAGARD LIQUID ERC at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity [see Dosage and Administration (2.3) , Warnings and Precautions (5.4) ] . WARNING: THROMBOSIS , RENAL DYSFUNCTION and ACUTE RENAL FAILURE See full prescribing information for complete boxed warning . Thrombosis may occur with immune globulin products, including GAMMAGARD LIQUID ERC. Risk factors include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity and cardiovascular risk factors. ( 5.4 ) Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients with immune globulin intravenous (IGIV) products including GAMMAGARD LIQUID ERC. Renal dysfunction and acute failure occur more commonly with IGIV products containing sucrose. GAMMAGARD LIQUID ERC does not contain sucrose. ( 5.2 ) For patients at risk of thrombosis, administer GAMMAGARD LIQUID ERC at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity. ( 5.4 )
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings and cautions
5 WARNINGS AND PRECAUTIONS Hypersensitivity Reactions: In case of a severe hypersensitivity reaction, discontinue GAMMAGARD LIQUID ERC infusion, and manage as appropriate. ( 5.1 ) Renal Injury: Ensure patients are not volume depleted before administering GAMMAGARD LIQUID ERC. Monitor renal function, including blood urea nitrogen, serum creatinine, and urine output in patients receiving GAMMAGARD LIQUID ERC prior to initial infusion and at appropriate intervals thereafter. ( 5.2 ) Hyperproteinemia, hyperviscosity, and hyponatremia may occur. ( 5.3 ) Thrombosis: Monitor for signs and symptoms of thrombosis. ( 5.4 ) Aseptic Meningitis Syndrome (AMS): Conduct neurological examination on patients exhibiting symptoms and signs of AMS. ( 5.5 ) Hemolysis: Monitor for clinical signs and symptoms of hemolysis. ( 5.6 ) Transfusion-Related Acute Lung Injury (TRALI): Monitor patients for symptoms of TRALI and manage using oxygen therapy with adequate ventilatory support as appropriate. ( 5.7 ) Transmission of infectious disease: GAMMAGARD LIQUID ERC is made from human blood, it may carry a risk of transmitting infectious agents. ( 5.8 ) 5.1 Hypersensitivity Reactions Severe hypersensitivity reactions may occur after treatment with immune globulin products, including GAMMAGARD LIQUID ERC, even in patients previously treated with immune globulin products. Patients with known antibodies to IgA may have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions. In case of severe hypersensitivity, discontinue GAMMAGARD LIQUID ERC infusion immediately and manage with appropriate medications which may include epinephrine for immediate treatment. GAMMAGARD LIQUID ERC contains IgA less than or equal to 2 µg/mL in a 10% solution. The concentration of IgA that will not provoke a reaction is not known, and therefore all immunoglobulin products, including GAMMAGARD LIQUID ERC, carry the risk of inducing an anaphylactic reaction to IgA. 5.2 Renal Injury Renal injury including acute renal failure, acute tubular necrosis, proximal tubular nephropathy, and osmotic nephrosis may occur after treatment with immune globulin products, including GAMMAGARD LIQUID ERC. Ensure patients are not volume depleted before administering GAMMAGARD LIQUID ERC. In patients who are at risk of renal injury because of pre-existing renal insufficiency or predisposition to acute renal failure (such as diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs, etc.), administer GAMMAGARD LIQUID ERC at the minimum rate of infusion practicable [see Dosage and Administration (2.3) ] . Assess renal function, including measurement of blood urea nitrogen (BUN), serum creatinine, and urine output in patients receiving GAMMAGARD LIQUID ERC prior to initial infusion and at appropriate intervals thereafter. If renal function deteriorates, consider discontinuation of GAMMAGARD LIQUID ERC [see Dosage and Administration (2.3) ] . 5.3 Hyperproteinemia, Hyperviscosity, and Hyponatremia Hyperproteinemia, hyperviscosity, and hyponatremia may occur in patients receiving immune globulin products, including GAMMAGARD LIQUID ERC. Distinguish true hyponatremia from pseudohyponatremia that is temporally or causally related to hyperproteinemia with concomitant decreased calculated serum osmolality or elevated osmolar gap. Treatment aimed at decreasing serum free water in patients with pseudohyponatremia may lead to volume depletion and hyperviscosity and a predisposition to thromboembolic events. 5.4 Thrombosis Thrombosis may occur following treatment with immune globulin products, including GAMMAGARD LIQUID ERC. Risk factors include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. Ensure adequate hydration in patients before administration of GAMMAGARD LIQUID ERC. For patients at risk of thrombosis, administer GAMMAGARD LIQUID ERC at the minimum dose and infusion rate practicable. Monitor patients for signs and symptoms of thrombosis. Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including patients with cryoglobulins, fasting chylomicronemia, high triacylglycerols (triglycerides), or monoclonal gammopathies [see Boxed Warning , Dosage and Administration (2.3) ] . 5.5 Aseptic Meningitis Syndrome Aseptic meningitis syndrome (AMS) may occur with immune globulin products, including GAMMAGARD LIQUID ERC. The risk of AMS may be higher with high doses (2 g/kg) and/or rapid infusion of immunoglobulin products. Signs and symptoms of AMS include severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements, nausea and vomiting. AMS usually begins within several hours to 2 days following immune globulin treatment. Conduct neurological examination on patients exhibiting symptoms and signs of AMS, including Cerebrospinal fluid (CSF) studies, to rule out other causes of meningitis. CSF studies frequently reveal pleocytosis up to several thousand cells per cubic millimeter, elevated protein levels up to several hundred mg/dL, and negative culture results. Discontinuation of immune globulin treatment has resulted in remission of AMS within several days without sequelae. 5.6 Hemolysis Hemolysis may occur with immune globulin products, including GAMMAGARD LIQUID ERC due to the presence of blood group antibodies that may act as hemolysins and induce in vivo coating of red blood cells (RBC). This may cause a positive direct antiglobulin test [DAT (Coombs test)]. Delayed hemolytic anemia can develop after GAMMAGARD LIQUID ERC therapy due to enhanced RBC sequestration [see Adverse Reactions (6) ] . The risk factors for hemolysis include high doses (e.g., ≥2 g/kg, either as a single administration or divided over several days), non-O blood group, and underlying inflammatory disease condition. Monitor patients for signs and symptoms of hemolysis. Conduct appropriate laboratory testing in higher risk patients, including measurement of hemoglobin or hematocrit prior to infusion and within approximately 36 to 96 hours post-infusion. If signs and symptoms of hemolysis are observed, perform additional confirmatory laboratory testing [see Warnings and Precautions (5.9) ] . 5.7 Transfusion-Related Acute Lung Injury Transfusion-Related Acute Lung Injury (TRALI) may occur following treatment with immune globulin products, including GAMMAGARD LIQUID ERC. Symptoms typically occur within 1 to 6 hours after treatment and may include severe respiratory distress, pulmonary edema, hypoxemia, normal left ventricular function, and fever. Monitor patients for signs and symptoms of TRALI. If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil and anti-HLA antibodies in both the product and patient serum. Manage patients using oxygen therapy with ventilatory support as appropriate. 5.8 Transmission Infectious Agents There is risk of transmission of infectious disease or agents including viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and the Creutzfeldt-Jakob disease agent with GAMMAGARD LIQUID ERC administration because it is manufactured using human blood. The risk of infectious agent transmission is minimized by plasma donor screening, donation testing, and manufacturing steps proven to inactivate and remove bloodborne pathogens. All infections thought by a physician to possibly have been transmitted by this product should be reported by to Takeda Pharmaceuticals U.S.A., Inc at 1-877-TAKEDA-7 (1-877-825-3327) (in the U.S.). 5.9 Monitoring Laboratory Tests Assess renal function including measurement of blood urea nitrogen (BUN) and serum creatinine before the initial infusion of GAMMAGARD LIQUID ERC and at appropriate intervals thereafter. Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia, high triacylglycerols (triglycerides), or monoclonal gammopathies, because of the potentially increased risk of thrombosis. If signs and/or symptoms of hemolysis are present after an infusion of GAMMAGARD LIQUID ERC, perform appropriate laboratory testing for confirmation. If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies and anti-HLA antibodies in both the product and the patient's serum. 5.10 Interference with Laboratory Tests False positive serological testing results including a positive direct or indirect antiglobulin (Coombs) test may occur after administration of immune globulin products, including GAMMAGARD LIQUID ERC due to the transitory rise of various passively transferred antibodies. Administration of immune globulin products, including GAMMAGARD LIQUID ERC, can lead to false positive readings in assays that depend on detection of beta-D-glucans for diagnosis of fungal infections; this may persist during the weeks following infusion of the product.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The most common adverse reactions (incidence ≥5%) were: ( 6.1 ) Intravenous Administration : Headache, fatigue, pyrexia, chills, nausea, pain in extremity, diarrhea, migraine, vomiting, dizziness, urticaria, cough, asthma, oropharyngeal pain, infusion site extravasation, arthralgia, rash, myalgia, pruritus, and cardiac murmur. ( 6.1 ) Subcutaneous Administration : Infusion site (local) event, headache, pyrexia, fatigue, heart rate increased, abdominal pain upper, vomiting, arthralgia, nausea, asthma, blood pressure systolic increased, diarrhea, ear pain, aphthous ulcer, migraine, oropharyngeal pain, and pain in extremity. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals U.S.A., Inc. at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. No clinical studies have been conducted using GAMMAGARD LIQUID ERC. The safety of GAMMAGARD LIQUID ERC in patients with primary humoral immunodeficiency (PI) is supported by two clinical studies conducted on GAMMAGARD LIQUID, Study 1 and Study 2 as described below. Study 1 The safety of GAMMAGARD LIQUID IV infusion was evaluated in Study 1 . A total of 61 patients received 1,811 infusions of GAMMAGARD LIQUID at a dose of 300 to 600 mg/kg every 21 to 28 days for 12 months [see Clinical Studies 14 ] . A total of 5 serious adverse reactions were reported in 4 patients (28%), including two cases of aseptic meningitis in one patient, stent placement, gastrointestinal hemorrhage, and encephalopathy. Out of these 5 serious adverse reactions, only 1 case of aseptic meningitis was deemed to be related by the investigator. Two patients were discontinued, likely due to adverse reactions, which were pruritic papular rash and aseptic meningitis. Table 4 : summarizes the most common adverse reactions occurring in ≥5% of patients in Study 1 . Table 4: Adverse Reactions Occurring in ≥5% of Patients in Study 1 Adverse Reactions Adverse reactions were defined as adverse events occurring during or within 72 hours of infusion or any causally related event occurring within the study period. By Infusion N (%) (N=1,811 Infusions) By Patient N (%) (N=61 Patients) Headache 94 (5%) 29 (48%) Fatigue 33 (2%) 14 (23%) Pyrexia 28 (2%) 17 (28%) Chills 28 (2%) 12 (20%) Nausea 17 (0.9%) 11 (18%) Pain in extremity 13 (0.7%) 7 (11%) Diarrhea 12 (0.7%) 9 (15%) Migraine 12 (0.7%) 4 (7%) Vomiting 11 (0.6%) 9 (15%) Dizziness 11 (0.6%) 8 (13%) Urticaria 10 (0.6%) 6 (10%) Cough 9 (0.5%) 8 (13%) Asthma 7 (0.4%) 6 (10%) Oropharyngeal pain 7 (0.4%) 5 (8%) Infusion site extravasation 7 (0.4%) 4 (7%) Arthralgia 6 (0.3%) 5 (8%) Rash 6 (0.3%) 4 (7%) Myalgia 5 (0.3%) 5 (8%) Pruritus 5 (0.3%) 4 (7%) Cardiac murmur 4 (0.2%) 4 (7%) Study 2 The safety of GAMMAGARD LIQUID SC infusion was evaluated in Study 2 . A total of 47 patients received 2,294 SC infusions of GAMMAGARD LIQUID at a mean dose of 182 to 191 mg/kg/week for a median duration of 379 days (range 57 to 477 days) [see Clinical Studies 14 ] . One serious adverse reaction of chest pain was reported in 1 patient (2%). One patient discontinued likely due to adverse reactions of fatigue and malaise. Table 5 summarizes the most common adverse reactions occurring in ≥5% of patients in Study 2 . Table 5: Adverse Reactions Occurring in ≥5% of Patients in Study 2 Adverse Reactions Adverse reactions were defined as adverse events occurring during or within 72 hours of infusion or any causally related event occurring within the study period. By Infusion N (%) (N=2294 Infusions) By Patient N (%) (N=47 Patients) Infusion site (local) event included rash, erythema, edema, hemorrhage, pain, hematoma, pruritus, and swelling. 55 (2%) 21 (45%) Headache 31 (1%) 19 (40%) Pyrexia 11 (0.5%) 9 (19%) Fatigue 11 (0.5%) 7 (15%) Heart rate increased 11 (0.5%) 3 (6%) Abdominal pain upper 9 (0.4%) 5 (11%) Vomiting 7 (0.3%) 5 (11%) Arthralgia 7 (0.3%) 3 (6%) Nausea 7 (0.3%) 3 (6%) Asthma 6 (0.3%) 4 (9%) Blood pressure systolic increased 6 (0.3%) 3 (6%) Diarrhea 5 (0.2%) 3 (6%) Ear pain 4 (0.2%) 3 (6%) Aphthous ulcer 3 (0.1%) 3 (6%) Migraine 3 (0.1%) 3 (6%) Oropharyngeal pain 3 (0.1%) 3 (6%) Pain in extremity 3 (0.1%) 3 (6%) 6.2 Postmarketing Experience Because adverse reactions are reported voluntarily post-approval from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to product exposure. GAMMAGARD LIQUID The following adverse reactions have been identified during postmarketing use of GAMMAGARD LIQUID. Intravenous Administration Blood and Lymphatic System Disorders: Hemolysis Immune System Disorders: Anaphylactic shock Nervous System Disorders: Cerebral vascular accident, Transient ischemic attack, Tremor Cardiac Disorders: Myocardial infarction Vascular Disorders: Deep vein thrombosis, Hypotension Respiratory, Thoracic and Mediastinal Disorders: Pulmonary embolism, Pulmonary edema, Chest pain, Transfusion-related acute lung injury Skin and Subcutaneous Tissue Disorders: Hyperhidrosis Investigations: Coombs direct test positive, Oxygen saturation decreased Subcutaneous Administration Immune System Disorders: Hypersensitivity Musculoskeletal and Connective Tissue Disorders: Myalgia General Disorders and Administration Site Conditions: Chills GENERAL In addition to the adverse reactions listed above, the following adverse reactions have been identified for immune globulin products. Blood and Lymphatic System Disorder: Hemolytic anemia, Pancytopenia Nervous System Disorders: Aseptic meningitis, Coma, Seizures, Loss of consciousness, Paresthesia, Lethargy Cardiac Disorders: Arrhythmia, Tachycardia, Cardiac arrest Vascular Disorders: Flushing, Vascular collapse Respiratory, Thoracic and Mediastinal Disorders: Cyanosis, Hypoxemia, Bronchospasm, Apnea, Acute Respiratory Distress Syndrome (ARDS), Dyspnea, Laryngospasm, Renal and Urinary Disorders: Renal impairment, Osmotic nephropathy Skin and Subcutaneous Tissue Disorders: Bullous dermatitis, Epidermolysis, Erythema multiforme, Stevens-Johnson Syndrome Gastrointestinal Disorders: Hepatic dysfunction General Disorders and Administration Site Conditions: Malaise, Fever, Injection site reaction (including induration, warmth)
adverse reactions table
<table ID="table4" width="80%"><caption>Table 4: Adverse Reactions Occurring in ≥5% of Patients in Study 1</caption><col width="30%" align="left"/><col width="30%" align="left"/><col width="40%" align="left"/><thead><tr styleCode="Botrule"><th styleCode="Lrule Rrule">Adverse Reactions<footnote>Adverse reactions were defined as adverse events occurring during or within 72 hours of infusion or any causally related event occurring within the study period.</footnote></th><th styleCode="Rrule">By Infusion N (%) (N=1,811 Infusions)</th><th styleCode="Rrule">By Patient N (%) (N=61 Patients)</th></tr></thead><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Headache</td><td styleCode="Rrule">94 (5%)</td><td styleCode="Rrule">29 (48%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Fatigue</td><td styleCode="Rrule">33 (2%)</td><td styleCode="Rrule">14 (23%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Pyrexia</td><td styleCode="Rrule">28 (2%)</td><td styleCode="Rrule">17 (28%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Chills</td><td styleCode="Rrule">28 (2%)</td><td styleCode="Rrule">12 (20%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Nausea</td><td styleCode="Rrule">17 (0.9%)</td><td styleCode="Rrule">11 (18%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Pain in extremity</td><td styleCode="Rrule">13 (0.7%)</td><td styleCode="Rrule">7 (11%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Diarrhea</td><td styleCode="Rrule">12 (0.7%)</td><td styleCode="Rrule">9 (15%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Migraine</td><td styleCode="Rrule">12 (0.7%)</td><td styleCode="Rrule">4 (7%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Vomiting</td><td styleCode="Rrule">11 (0.6%)</td><td styleCode="Rrule">9 (15%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Dizziness</td><td styleCode="Rrule">11 (0.6%)</td><td styleCode="Rrule">8 (13%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Urticaria</td><td styleCode="Rrule">10 (0.6%)</td><td styleCode="Rrule">6 (10%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Cough</td><td styleCode="Rrule">9 (0.5%)</td><td styleCode="Rrule">8 (13%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Asthma</td><td styleCode="Rrule">7 (0.4%)</td><td styleCode="Rrule">6 (10%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Oropharyngeal pain</td><td styleCode="Rrule">7 (0.4%)</td><td styleCode="Rrule">5 (8%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Infusion site extravasation</td><td styleCode="Rrule">7 (0.4%)</td><td styleCode="Rrule">4 (7%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Arthralgia</td><td styleCode="Rrule">6 (0.3%)</td><td styleCode="Rrule">5 (8%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Rash</td><td styleCode="Rrule">6 (0.3%)</td><td styleCode="Rrule">4 (7%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule Botrule">Myalgia</td><td styleCode="Rrule Botrule">5 (0.3%)</td><td styleCode="Rrule Botrule">5 (8%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Pruritus</td><td styleCode="Rrule">5 (0.3%)</td><td styleCode="Rrule">4 (7%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Cardiac murmur</td><td styleCode="Rrule">4 (0.2%)</td><td styleCode="Rrule">4 (7%)</td></tr></tbody></table>
adverse reactions table
<table ID="table5" width="80%"><caption>Table 5: Adverse Reactions Occurring in ≥5% of Patients in Study 2</caption><col width="30%" align="left"/><col width="30%" align="left"/><col width="40%" align="left"/><thead><tr styleCode="Botrule"><th styleCode="Lrule Rrule">Adverse Reactions<footnote>Adverse reactions were defined as adverse events occurring during or within 72 hours of infusion or any causally related event occurring within the study period.</footnote></th><th styleCode="Rrule">By Infusion N (%) (N=2294 Infusions)</th><th styleCode="Rrule">By Patient N (%) (N=47 Patients)</th></tr></thead><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Infusion site (local) event<footnote>included rash, erythema, edema, hemorrhage, pain, hematoma, pruritus, and swelling.</footnote></td><td styleCode="Rrule">55 (2%)</td><td styleCode="Rrule">21 (45%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Headache</td><td styleCode="Rrule">31 (1%)</td><td styleCode="Rrule">19 (40%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Pyrexia</td><td styleCode="Rrule">11 (0.5%)</td><td styleCode="Rrule">9 (19%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Fatigue</td><td styleCode="Rrule">11 (0.5%)</td><td styleCode="Rrule">7 (15%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Heart rate increased</td><td styleCode="Rrule">11 (0.5%)</td><td styleCode="Rrule">3 (6%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Abdominal pain upper</td><td styleCode="Rrule">9 (0.4%)</td><td styleCode="Rrule">5 (11%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Vomiting</td><td styleCode="Rrule">7 (0.3%)</td><td styleCode="Rrule">5 (11%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Arthralgia</td><td styleCode="Rrule">7 (0.3%)</td><td styleCode="Rrule">3 (6%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Nausea</td><td styleCode="Rrule">7 (0.3%)</td><td styleCode="Rrule">3 (6%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Asthma</td><td styleCode="Rrule">6 (0.3%)</td><td styleCode="Rrule">4 (9%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Blood pressure systolic increased</td><td styleCode="Rrule">6 (0.3%)</td><td styleCode="Rrule">3 (6%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Diarrhea</td><td styleCode="Rrule">5 (0.2%)</td><td styleCode="Rrule">3 (6%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Ear pain</td><td styleCode="Rrule">4 (0.2%)</td><td styleCode="Rrule">3 (6%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Aphthous ulcer</td><td styleCode="Rrule">3 (0.1%)</td><td styleCode="Rrule">3 (6%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Migraine</td><td styleCode="Rrule">3 (0.1%)</td><td styleCode="Rrule">3 (6%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Oropharyngeal pain</td><td styleCode="Rrule">3 (0.1%)</td><td styleCode="Rrule">3 (6%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Pain in extremity</td><td styleCode="Rrule">3 (0.1%)</td><td styleCode="Rrule">3 (6%)</td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.